Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.
Ann-Lii Cheng, MD
Advertisement
Articles by Ann-Lii Cheng, MD
Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Phase III Findings for Lenvatinib in HCCPublished: July 11th 2017 | Updated:
Moving Forward From Monotherapy in HCCPublished: October 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
